Vaccines

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

Historically, pneumococcal vaccination in adults has been reserved for those at heightened risk, with adults bearing the cost compared to free childhood vaccinations.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

Ongoing surveillance from the CDC and FDA will continue to evaluate the risk of Guillan-Barré syndrome to guide further ACIP recommendations.

The company’s mRNA 1345 vaccine was given the nod by the federal agency and is indicated for seniors for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD).

CDC has been tracking New York City varicella outbreak among migrants with over 870 cases reported since October 2022.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

This framework in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from animals to humans.

With 9 confirmed cases, recent incidences in schools and in the community, caregivers and individuals should stay informed if symptoms appear.

Recent study examines the relationship between COVID-19 vaccination and post-COVID conditions, shedding light on the potential long-term effects of vaccination.

Authorized for children in malaria-endemic regions, this vaccine aims to bridge the gap between demand and supply, offering hope against malaria's toll.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.

The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.

Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.

Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.

The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

The study findings imply newly available prevention strategies for which older children—ages 2 to 5 years—are not currently eligible should be prioritized.

The vaccine’s developer, YS Biopharma, will begin its phase 1 clinical trial in the Philippines this summer.

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

The Centers for Disease Control and Prevention (CDC) and Detroit Health Department stress the importance of vaccination and surveillance.

New data demonstrates protection against new variants.

The origins of the recent H5N1 (avian flu) case in Texas remain unknown, but a researcher offers insights into transmission between animals and humans, the likelihood of more cases, vaccine availability, and treatment.

The company is going to submit their data to the FDA to seek approval for people within this age group.

A study on Italian vaccination rates and factors influencing Rotavirus vaccine acceptance.

Trial examines high-dose vs. standard-dose influenza vaccines.